封面
市場調查報告書
商品編碼
1771617

美國創傷性腦損傷生物標記市場規模、佔有率、趨勢分析報告:按類型、樣本類型、應用、最終用途、細分預測,2025-2033

U.S. Traumatic Brain Injury Biomarkers Market Size, Share & Trends Analysis Report By Type (Protein Biomarkers, Genetic Biomarkers, Metabolomic Biomarkers), By Sample Type, By Application, By End Use, And Segment Forecasts, 2025 - 2033

出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢:

美國創傷性腦損傷生物標記市場規模預計在 2024 年為 4.096 億美元,預計到 2033 年將達到 18.5473 億美元,2025 年至 2033 年的複合年成長率為 18.8%。

由於對兒科 TBI 診斷的需求不斷增加、對腦損傷的認知和資金不斷增加以及學術界和工業界之間的合作不斷加速,美國創傷性腦損傷 (TBI) 生物標記市場正在經歷顯著成長。

創傷性腦損傷 (TBI) 是指頭部受到意外撞擊,可能導致輕度至重度神經損傷,甚至死亡。根據美國腦損傷協會 (Brain Injury Association of America) 2025 年的報告,美國約有 1,140 萬 40 歲及以上人士因創傷性腦損傷 (TBI) 而失去意識,目前處於殘疾狀態。此外,每年約有 290 萬例與 TBI 相關的急診就診,凸顯了腦損傷帶來的沉重醫療負擔。

兒童和青少年特別容易受到因跌倒、運動傷害和事故造成的 TBI 的影響。在美國,每年約有 50 萬次兒童 TBI 急診就診。雖然兒童死亡率總體較低,約佔所有 TBI 相關死亡人數的 5%,但如果考慮到生命損失年數和殘疾生活年數,其更廣泛的影響就顯而易見。這些長期影響在兒童中明顯大於成人,凸顯了兒童 TBI 對公共衛生和生活品質造成的嚴重且持久的負擔。兒科保健提供者擴大轉向生物標記診斷,以便做出更安全、更快速的決策,並減少不必要的輻射暴露,尤其是來自電腦斷層掃描的輻射暴露。

基於血液的生物標記提供了一種非侵入性且客觀的方法來評估年輕患者的損傷風險和嚴重程度。瑞士和西班牙知名醫院於2024年6月進行的一項合作研究發現,血液生物標記可以顯著改善兒童輕度創傷性腦損傷 (mTBI) 的診斷和治療。這項由ABCDx、日內瓦大學和Vall d'Hebron醫院參與的多中心研究強調了血液生物標記在準確區分有無顱內損傷 (ICI) 兒童方面的潛力。這可以減少不必要的電腦斷層掃描,縮短住院觀察期,並提高兒科mTBI護理的效率。

研究型大學、生物技術公司和醫療保健提供者之間的緊密合作正在推動生物標記的檢驗和商業化。研究機構正在與生物技術和診斷公司合作,將實驗室發現轉化為臨床試驗。新的臨床試驗在推動TBI診斷和治療方面具有巨大潛力。這些臨床試驗專注於評估創新的診斷工具和治療方法,可以為更有效、更及時的干涉鋪平道路,並有可能改變急性和長期TBI管理中的患者預後。此類夥伴關係有助於加速臨床試驗、FDA申報和市場准入。此外,數據資源和生物樣本庫的共用支持縱向研究,從而提高生物標記的可靠性。美國生態系統透過公私合作促進創新的能力,是擴大TBI生物標記市場的主要競爭優勢。

醫療、社會和製度因素的共同作用,推動了美國市場對TBI生物標記的資金投入增加。社會對TBI長期影響的認知不斷提高,尤其是在體育和軍事領域,這推動了對更準確、更及時的診斷工具的需求。傳統的影像學檢查通常無法檢測到輕微或早期損傷,因此需要基於生物標記的解決方案,以提供客觀、快速和非侵入性的評估。 2024年2月,美國指導醫學研究計畫 (CDMRP) 和美國醫學研究與發展司令部 (USAMRDC) 等政府機構將增加創傷性腦損傷和心理健康研究計畫 (TBIPHRP) 等計畫的投資。這些計畫旨在推動早期發現、治療和預防策略,同時應對TBI的心理影響。這些資金的湧入,加上商業化潛力和日益成長的創業投資興趣,正在加速創新,重塑美國TBI生物標記領域的格局。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國創傷性腦損傷生物標記市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/輔助市場展望。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國創傷性腦損傷生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國創傷性腦損傷生物標記市場:類型估計和趨勢分析

  • 2024 年及 2033 年各類型市場佔有率
  • 細分儀表板
  • 美國創傷性腦損傷生物標記市場:類型變異分析
  • 美國創傷性腦損傷生物標記市場規模與趨勢分析(2021-2033年)
  • 2021-2033年美國創傷性腦損傷生物標記市場收益估計及預測
  • 蛋白質生物標記
  • 基因生物標記
  • 代謝體學學生物標記

第5章美國創傷性腦損傷生物標記市場:樣本類型估計與趨勢分析

  • 樣本類型市場佔有率,2024 年和 2033 年
  • 細分儀表板
  • 美國創傷性腦損傷生物標記市場:樣本類型展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 以血液為基礎
  • 基於腦脊髓液(CSF)
  • 尿基

第6章美國創傷性腦損傷生物標記市場:應用評估與趨勢分析

  • 2024 年和 2033 年應用市場佔有率
  • 細分儀表板
  • 美國創傷性腦損傷生物標記市場:應用前景
  • 2021年至2033年市場規模、預測與趨勢分析
  • 診斷
  • 預後
  • 監測治療反應

第7章美國創傷性腦損傷生物標記市場:最終用途估計和趨勢分析

  • 2024年及2033年最終用途市場佔有率
  • 細分儀表板
  • 美國創傷性腦損傷生物標記市場:最終用途展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 醫院和診所
  • 診斷實驗室
  • 研究所

第8章美國創傷性腦損傷生物標記市場:國家估計和趨勢分析

  • 2024 年及 2033 年各國市場
  • 各國市場儀表板
  • 美國市場概述
  • 市場規模、預測趨勢分析,2021-2033年:
  • 美國
    • 主要國家趨勢
    • 法規結構/報銷
    • 競爭場景

第9章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Quanterix.
    • Banyan Biomarkers, Inc.
    • Abbott
    • GE Healthcare.
    • Thermo Fisher Scientific Inc.
    • Immunarray.
    • Oculogica
    • NeuroTrauma Sciences, LLC
    • BRAINBox Solutions, Inc.
    • Myriad Genetics, Inc.
    • Abcam Limited
Product Code: GVR-4-68040-622-2

Market Size & Trends:

The U.S. traumatic brain injury biomarkers market size was estimated at USD 409.60 million in 2024, is projected to reach 1,854.73 million by 2033, and is forecasted to grow at a CAGR of 18.8% from 2025 to 2033. The U.S. traumatic brain injury (TBI) biomarkers market is expanding significantly due to increasing demand for pediatric TBI diagnosis, growing awareness and funding related to brain injury, and accelerating collaboration between academic institutions and industry.

TBI refers to an unintentional impact to the head that can lead to outcomes ranging from mild impairment to severe neurological damage or even death. According to a report by the Brain Injury Association America, 2025, the U.S. reported approximately 11.4 million individuals over the age of 40 who experienced a traumatic brain injury (TBI) resulting in loss of consciousness are currently living with a disability. In addition, around 2.9 million TBI-related emergency department visits are reported each year, indicating the significant healthcare burden associated with brain injuries.

Children and adolescents are particularly vulnerable to TBIs from falls, sports injuries, and accidents, yet symptoms can be subtle or delayed. Every year in the U.S., pediatric TBI leads to an estimated 500,000 emergency department visits. While children have a lower overall mortality rate, accounting for about 5% of all TBI-related deaths, the broader impact is more evident when considering years of life lost and years lived with disability. These long-term effects are notably greater in children than in adults, with the serious and lasting burden pediatric TBI poses on public health and quality of life. Pediatric care providers are increasingly turning to biomarker diagnostics to make safer and faster decisions, especially to reduce unnecessary radiation exposure from CT scans.

Blood-based biomarkers offer a non-invasive, objective method to assess injury risk and severity in young patients. A collaborative study conducted in June 2024, by renowned hospitals in Switzerland and Spain, discovered potential blood biomarkers that could significantly improve the diagnosis and management of mild traumatic brain injury (mTBI) in children. This multi-center research, involving ABCDx, the University of Geneva, and Vall d'Hebron Hospital, highlighted the potential of these blood biomarkers to accurately differentiate children with intracranial injuries (ICI) from those without. This reduced unnecessary CT scans and shorter hospital observation periods, improving efficiency in pediatric mTBI care.

Strong collaboration between research universities, biotech companies, and healthcare providers is advancing biomarker validation and commercialization. Institutions are working with biotech and diagnostics companies to translate laboratory discoveries into clinical tests. A new clinical trial holds significant promise for advancing the diagnosis and treatment of TBI. Focused on evaluating innovative diagnostic tools or therapeutic approaches, this trial could pave the way for more effective and timely interventions, potentially transforming patient outcomes in acute and long-term TBI management. These partnerships help accelerate clinical trials, FDA submissions, and market entry. In addition, shared data resources and biobanks support longitudinal studies that strengthen biomarker credibility. The U.S. ecosystem's ability to foster innovation through public-private-academic collaboration is a major competitive advantage in expanding the TBI biomarker market.

A convergence of medical, social, and institutional factors drives rising funding for TBI biomarkers in the U.S. market. Growing public awareness of TBIs' long-term consequences, particularly in sports and military populations, has amplified demand for more accurate and timely diagnostic tools. Traditional imaging often falls short in detecting mild or early-stage injuries, creating a critical need for biomarker-based solutions to provide objective, rapid, and non-invasive assessments. In February 2024, government agencies such as the Congressionally Directed Medical Research Programs (CDMRP) and the U.S. Army Medical Research and Development Command (USAMRDC) have increased investments in initiatives like the Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP). These efforts aim to advance early detection, treatment, and prevention strategies, while also addressing the psychological effects of TBI. Coupled with growing commercialization potential and venture capital interest, this influx of funding is accelerating innovation and reshaping the TBI biomarker landscape in the United States.

U.S. Traumatic Brain Injury Biomarkers Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented U.S. traumatic brain injury biomarkers market report based on type, sample type, application, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Protein Biomarkers
  • Genetic Biomarkers
  • Metabolomic Biomarkers
  • Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Blood-based
  • Cerebrospinal fluid (CSF)-based
  • Urine-based
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnosis
  • Prognosis
  • Monitoring treatment response
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Sample Type
    • 1.2.3. Application
    • 1.2.4. End user
    • 1.2.5. Country scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Sample type outlook
    • 2.2.3. Application outlook
    • 2.2.4. End use outlook
    • 2.2.5. Country outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Traumatic Brain Injury Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Traumatic Brain Injury Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Traumatic Brain Injury Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Traumatic Brain Injury Biomarkers Market: Type Movement Analysis
  • 4.4. U.S. Traumatic Brain Injury Biomarkers Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
  • 4.5. U.S. Traumatic Brain Injury Biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Protein biomarkers
    • 4.6.1. Protein biomarkers Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7. Genetic biomarkers
    • 4.7.1. Genetic biomarkers Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.8. Metabolomic biomarkers
    • 4.8.1. Metabolomic biomarkers Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Traumatic Brain Injury Biomarkers Market: Sample type Estimates & Trend Analysis

  • 5.1. Sample type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Traumatic Brain Injury Biomarkers Market by Sample type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Blood-based
    • 5.5.1. Blood-based Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Cerebrospinal fluid (CSF)-based
    • 5.6.1. Cerebrospinal fluid (CSF)-based Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.7. Urine-based
    • 5.7.1. Urine-based Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Traumatic Brain Injury Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. U.S. Traumatic Brain Injury Biomarkers Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Diagnosis
    • 6.5.1. Diagnosis Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Prognosis
    • 6.6.1. Prognosis Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Monitoring treatment response
    • 6.7.1. Monitoring treatment response, Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Traumatic Brain Injury Biomarkers Market: End use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. U.S. Traumatic Brain Injury Biomarkers Market by End use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Hospitals & Clinics
    • 7.5.1. Hospitals & Clinics Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Diagnostic Laboratories
    • 7.6.1. Diagnostic Laboratories Market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. Research Institutes
    • 7.7.1. Research Institutes Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Traumatic Brain Injury Biomarkers Market: Country Estimates & Trend Analysis

  • 8.1. Country Market Share Analysis, 2024 & 2033
  • 8.2. Country Market Dashboard
  • 8.3. U.S. Country Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. U.S.
    • 8.5.1. Key country dynamics
    • 8.5.2. Regulatory framework/Reimbursement
    • 8.5.3. Competitive scenario
    • 8.5.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Quanterix.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Services benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Banyan Biomarkers, Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Services benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Abbott
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Services benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. GE Healthcare.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Services benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Thermo Fisher Scientific Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Services benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Immunarray.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Services benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Oculogica
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Services benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. NeuroTrauma Sciences, LLC
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Services benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. BRAINBox Solutions, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Services benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Myriad Genetics, Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Services benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Abcam Limited
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Services benchmarking
      • 9.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 3 U.S Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 4 U.S Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 5 U.S Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in the U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Traumatic Brain Injury biomarkers market: market outlook
  • Fig. 10 U.S. Traumatic Brain Injury biomarkers competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Traumatic Brain Injury Biomarkers Market Driver Impact
  • Fig. 16 U.S. Traumatic Brain Injury Biomarkers market restraint impact
  • Fig. 17 U.S. Traumatic Brain Injury Biomarkers Market Strategic Initiatives Analysis
  • Fig. 18 U.S. Traumatic Brain Injury Biomarkers market: Type movement analysis
  • Fig. 19 U.S. Traumatic Brain Injury Biomarkers market: Type outlook and key takeaways
  • Fig. 20 Protein biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 21 Genetic biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 22 Metabolomic biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 23 U.S. Traumatic Brain Injury Biomarkers Market: Sample type movement analysis
  • Fig. 24 U.S. Traumatic Brain Injury Biomarkers market: Sample type outlook and key takeaways
  • Fig. 25 Blood-based market estimates and forecasts, 2021 - 2033
  • Fig. 26 Cerebrospinal fluid (CSF)-based market estimates and forecasts, 2021 - 2033
  • Fig. 27 Urine-based market estimates and forecasts, 2021 - 2033
  • Fig. 28 U.S. Traumatic Brain Injury Biomarkers Market: Application movement analysis
  • Fig. 29 U.S. Traumatic Brain Injury Biomarkers market: Application outlook and key takeaways
  • Fig. 30 Diagnosis market estimates and forecasts, 2021 - 2033
  • Fig. 31 Prognosis market estimates and forecasts, 2021 - 2033
  • Fig. 32 Monitoring treatment response market estimates and forecasts, 2021 - 2033
  • Fig. 33 U.S. Traumatic Brain Injury Biomarkers Market: End use movement analysis
  • Fig. 34 U.S. Traumatic Brain Injury Biomarkers market: End use outlook and key takeaways
  • Fig. 35 Hospitals & Clinics market estimates and forecasts, 2021 - 2033
  • Fig. 36 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 37 Research Institutes market estimates and forecasts, 2021 - 2033
  • Fig. 38 U.S. Traumatic Brain Injury Biomarkers market: Country movement analysis
  • Fig. 39 U.S. Traumatic Brain Injury Biomarkers market: Country outlook and key takeaways
  • Fig. 40 U.S. Traumatic Brain Injury Biomarkers market share and leading players
  • Fig. 41 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 42 Market share of key market players- U.S. Traumatic Brain Injury biomarkers market